U.S. Diabetes Market Set to Surge 60% by 2031 Amid GLP-1 Innovations and CGM Expansion

, /PRNewswire/ - A new U.S. diabetes market report provides essential insights into the rapid transformation of this market, fueled by breakthrough GLP-1 agonist drugs and advancements in continuous glucose monitoring (CGM) technologies. Produced by iData Research, a leading medical consulting and market research firm, the report delivers a deep dive into market trends, competitive landscape, regulatory shifts, and emerging opportunities that will impact the adoption and profitability of a market projected to exceed 60%, reaching nearly $80 billion by 2031.

The Boom of GLP-1 Agonists

GLP-1 receptor agonists are revolutionizing diabetes and obesity care, providing benefits beyond glucose control, including weight loss, cardiovascular health, and reduced kidney disease risk. The market is experiencing intense competition among key players:

• Novo Nordisk dominates with its semaglutide-based Ozempic^®, Rybelsus^®, and Wegovy^®, offering injectable and oral solutions. Additionally, Victoza^® and Saxenda^® cater to younger diabetes and weight-management patients.
• Eli Lilly counters with its tirzepatide-based Mounjaro^® and Zepbound^®, alongside Trulicity^®, a key player in adolescent diabetes treatment.
• Sanofi expands its global footprint with lixisenatide-based SOLIQUA^®, available in 84 countries.
• AstraZeneca, despite discontinuing Byetta^® and BYDUREON BCise^® in 2024, is investing heavily in new GLP-1 therapies, including a $185 million deal for an experimental Chinese GLP-1 treatment.

The Expansion of Continuous and Flash Glucose Monitoring

CGM technology has become essential for diabetes management, with the market poised for significant growth:

• Dexcom leads the CGM sector, leveraging its G6^® and G7^® devices alongside strategic partnerships with Insulet, Eli Lilly, Novo Nordisk, and others to integrate CGM with insulin delivery systems.
• Abbott, a strong competitor in both CGM and flash glucose monitoring (FGM), has secured a price-sensitive market share with FreeStyle Libre™, now worth nearly $1 billion in the United States. The company continues to innovate with Libre Rio™, aimed at affordability and accessibility.
• Medtronic offers the MiniMed™ 780G system, integrating Guardian™ 4 CGM sensors for automated insulin delivery.
• Senseonics is emerging with its long-term implantable Eversense^® CGM devices, carving out a niche in the market.

Key Market Drivers and Challenges

• Diabetes and Obesity Epidemic – Over 38 million Americans currently live with diabetes, with 40% of U.S. adults classified as obese. The increasing prevalence of type 2 diabetes (90-95% of cases) is driving demand for innovative treatments.
• Cost and Insurance Barriers – GLP-1 treatments and CGM systems remain expensive, limiting access for uninsured and low-income patients. Insurance restrictions and state-by-state policy variations add complexity to market adoption.

The Future of Diabetes Care

"The U.S. diabetes market is on a strong growth trajectory, with GLP-1 drugs and CGM technologies leading the charge," says Dr. Kamran Zamanian, CEO of iData Research, "Overcoming cost and coverage barriers could unlock even greater expansion, making advanced diabetes management more accessible."

Who Should Read This Report?

This report is designed for CEOs, CFOs, product and marketing managers, as well as strategic decision-makers within medical device companies looking to make data-driven decisions in the high-growth diabetes sector.

Get the Full Report

Access the U.S. Diabetes Monitoring, Treatment and Drug Delivery Market Report, or contact marketing at [email protected] to learn more and see detailed insights into market drivers, growth projections, and strategic opportunities.

SOURCE iData Research Inc.